Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi weekly Stock Chart
SNY [NASD]
Sanofi
Index- P/E21.38 EPS (ttm)1.98 Insider Own16.40% Shs Outstand2.51B Perf Week0.91%
Market Cap106.02B Forward P/E12.09 EPS next Y3.50 Insider Trans0.00% Shs Float2.23B Perf Month2.60%
Income4.96B PEG2.74 EPS next Q0.74 Inst Own7.80% Short Float0.10% Perf Quarter3.55%
Sales40.51B P/S2.62 EPS this Y15.50% Inst Trans0.95% Short Ratio2.06 Perf Half Y-5.35%
Book/sh26.25 P/B1.61 EPS next Y8.17% ROA- Target Price52.00 Perf Year9.51%
Cash/sh- P/C- EPS next 5Y7.80% ROE- 52W Range37.67 - 45.62 Perf YTD-2.60%
Dividend1.74 P/FCF- EPS past 5Y4.80% ROI5.00% 52W High-7.32% Beta0.53
Dividend %4.12% Quick Ratio- Sales past 5Y2.70% Gross Margin68.30% 52W Low12.24% ATR0.66
Employees104226 Current Ratio- Sales Q/Q7.20% Oper. Margin18.30% RSI (14)51.87 Volatility1.33% 1.22%
OptionableYes Debt/Eq- EPS Q/Q12.00% Profit Margin16.40% Rel Volume1.09 Prev Close42.11
ShortableYes LT Debt/Eq- EarningsApr 26 BMO Payout0.00% Avg Volume1.09M Price42.28
Recom1.50 SMA200.41% SMA50-1.60% SMA200-2.11% Volume1,194,253 Change0.40%
Dec-11-18Upgrade Jefferies Hold → Buy
Nov-01-18Upgrade Barclays Underweight → Equal Weight
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Neutral → Buy
Aug-10-18Upgrade Citigroup Neutral → Buy
Mar-23-18Upgrade Liberum Hold → Buy
Jan-23-18Downgrade Barclays Equal Weight → Underweight
Dec-06-17Downgrade BofA/Merrill Buy → Neutral
Dec-01-17Downgrade Morgan Stanley Overweight → Underweight
Nov-15-17Upgrade Barclays Underweight → Equal Weight
Aug-30-17Upgrade HSBC Securities Reduce → Hold
May-11-17Downgrade Berenberg Buy → Hold
Apr-07-17Downgrade HSBC Securities Hold → Reduce
Apr-06-17Initiated Argus Buy $50
Mar-09-17Initiated Liberum Hold
Nov-07-16Initiated Goldman Neutral
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-23-19 10:03AM  Alphabet to Aid Pharma Giants Enhance Clinical Trial Process Zacks
09:08AM  Lilly (LLY) Launches Half-Priced Version of Humalog Insulin Zacks
May-21-19 06:31AM  Is Sanofi (EPA:SAN) Trading At A 32% Discount? Simply Wall St.
May-16-19 08:20AM  Pfizer's Eczema Candidate Meets All Goals in Phase III Study Zacks
May-15-19 05:00PM  Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019 PR Newswire
08:04AM  Sanofi Joins Drugmakers' Bid to Treat Patients With Software Bloomberg
May-10-19 10:21AM  Inovio (INO) Q1 Earnings & Revenues Fall Short of Estimates Zacks
May-08-19 01:12PM  Sanofi Recognized by DiversityInc as a Top 50 Company PR Newswire
09:37AM  Here's the Bad News That Derailed Regeneron's Stock Motley Fool
08:45AM  Sanofi Announces Licensing of Dupixent® (dupilumab) in the EU for the Treatment of Severe Asthma With Type 2 Inflammation PR Newswire
May-07-19 11:52AM  Regeneron Pharmaceuticals Earnings: REGN Stock Drops on Q1 Miss InvestorPlace -5.28%
08:00AM  How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support Investor's Business Daily
May-06-19 04:15PM  A Single Rival Caused 2 Biopharma Stocks To Slip Here's Why Investor's Business Daily
09:21AM  The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo Zacks
May-03-19 03:41PM  Emergent (EBS) Earnings & Revenues Miss Estimates in Q1 Zacks
09:46AM  Drugmakers lobbying spending at 10-year high as Washington targets soaring prices MarketWatch
06:10AM  Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod Zacks
May-02-19 02:18PM  5 Biotech Stocks With Near-Term Catalysts Ahead Benzinga
10:00AM  Alnylam (ALNY) Reports Narrower-Than-Expected Loss in Q1 Zacks
08:16AM  The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data Benzinga
May-01-19 06:35PM  FDA approves Dengvaxia® for the prevention of dengue in individuals ages 9 through 16 living in U.S. endemic areas PR Newswire
09:28AM  What's in the Cards for Novavax (NVAX) This Earnings Season? Zacks
Apr-30-19 12:02PM  Sanofi: Annual General Meeting of April 30, 2019 GlobeNewswire
Apr-29-19 07:50PM  SoftBank Is Near $1 Billion Investment in Colombia's Rappi Bloomberg
Apr-27-19 11:44AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs Benzinga
Apr-26-19 08:09PM  U.S. FDA approves expanded label for Regeneron/Sanofi's cholesterol drug Reuters
04:33PM  Sanofi (SNY) Q1 2019 Earnings Call Transcript Motley Fool
02:04PM  BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat Zacks
09:29AM  Sanofi (SNY) Q1 Earnings Top, Genzyme & Vaccines Drive Sales Zacks
08:05AM  Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER PR Newswire
05:08AM  Sanofi: 1Q Earnings Snapshot Associated Press
03:57AM  Sanofi Profit Jumps on Sales of Vaccines and a Rising New Drug Bloomberg
03:20AM  AstraZeneca Cancer Drug Sales Fuel Profit Beating Estimates Bloomberg
02:18AM  Genzyme and vaccines push up Sanofi's first-quarter results Reuters
Apr-22-19 01:54PM  This Is Why You Shouldnt Count Regeneron Stock Out InvestorPlace
Apr-17-19 11:01AM  Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study Zacks
10:11AM  Sanofi Named One of America's Best Employers by Forbes PR Newswire
08:08AM  Boehringer's operating income flat as integration costs weigh Reuters
07:00AM  World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across the Globe PR Newswire
06:44AM  Boehringer's operating income flat as integration costs weigh Reuters
Apr-16-19 06:51AM  Does Sanofi (EPA:SAN) Have A Good P/E Ratio? Simply Wall St.
Apr-12-19 10:13AM  Opiant CEO, creator of Narcan, weighs in on opioid overdose crisis Yahoo Finance Video
Apr-11-19 02:43PM  Health Canada issues Notice of Compliance with Conditions (NOC/c) for LibtayoTM (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC) CNW Group
Apr-10-19 10:03AM  3 Biotech Stocks That Doubled After Hitting Bottom in 2018 Motley Fool
09:24AM  Sanofi sets a fixed price of insulin at $99 per month for some patients CNBC
05:04AM  Sanofi to cut U.S. insulin costs for some patients to $99 per month Reuters
05:00AM  Sanofi to cut U.S. insulin costs for some patients to $99 per month Reuters
05:00AM  Sanofi provides unprecedented access to its insulins for one set monthly price PR Newswire
Apr-09-19 10:59AM  Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth Zacks
09:03AM  Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics Zacks
Apr-08-19 09:10AM  Alnylam trades partner Sanofi for Regeneron in $800M deal American City Business Journals
Apr-02-19 10:51AM  Inovio Closes Enrollment in Brain Cancer Study Before Time Zacks
Apr-01-19 10:41AM  Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval Zacks
01:31AM  Sanofi: Availability of the Pre-quarterly Results Communication GlobeNewswire
Mar-29-19 12:45PM  Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates Benzinga
08:55AM  CDC: 44 States Still Reporting High Flu Activity Benzinga
Mar-28-19 10:43AM  AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes Zacks
Mar-27-19 10:48AM  Lilly (LLY) Signs New Immunology Deal With Private Biotech Zacks
06:41AM  Sanofi (EPA:SAN): What We Can Expect From This Growth Stock Simply Wall St.
Mar-26-19 09:29PM  Were Hedge Funds Right About Selling Sanofi (SNY)? Insider Monkey
Mar-25-19 04:26PM  Peninsula biotech lines up chance to crack the peanut allergy nut American City Business Journals
02:45PM  Ascendis Pivotal Growth Hormone Deficiency Study Data Positive Zacks
11:05AM  Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug Zacks
10:10AM  AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes Zacks
09:30AM  What's Next for Lexicon Pharmaceuticals? Motley Fool
Mar-24-19 09:00AM  Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals Motley Fool
Mar-22-19 04:46PM  This Pharma Giant Slipped After FDA Rejected Its Diabetes Treatment Investor's Business Daily
02:39PM  FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes Reuters
02:21PM  FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes Reuters
10:57AM  Biogen Stock Crashes on Termination of Alzheimer's Studies Zacks
Mar-20-19 11:24AM  Emergent Begins Phase III Study on Anthrax Vaccine AV7909 Zacks
Mar-19-19 04:05PM  Altimmune's Flu Shot Study: What You Need To Know Benzinga
Mar-18-19 06:59PM  Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent Zacks
01:15PM  Exclusive: Sanofi says working on CEO succession plan Reuters
12:34PM  Exclusive: Sanofi says working on CEO succession plan Reuters
11:36AM  Exclusive: Sanofi says working at hiring a new CEO Reuters
07:25AM  Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study Zacks
Mar-13-19 01:49PM  Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
10:46AM  Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News Zacks
09:35AM  Should Value Investors Consider Sanofi (SNY) Stock Now? Zacks
Mar-12-19 03:22PM  Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion Zacks
Mar-11-19 04:32PM  Regeneron/Sanofi wins U.S. approval for expanded use of skin drug Reuters
03:45PM  FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents PR Newswire
03:29PM  Regeneron/Sanofi skin disease drug cleared for use in U.S. teens Reuters
10:07AM  Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps Zacks
Mar-08-19 04:32PM  Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock? Investor's Business Daily
02:51PM  Sanofi: Filing of the 2018 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report GlobeNewswire
01:02AM  Sanofi: FDA to undertake priority review of Dupixent® (dupilumab) for adults with inadequately controlled severe chronic rhinosinusitis with nasal polyps GlobeNewswire
Mar-06-19 02:55PM  Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA Zacks
02:36PM  Top Stock Reports for Salesforce, Booking Holdings & VMware Zacks
08:16AM  3 Big Pharmas Trying to Pop the Rebate Bubble Motley Fool
Mar-05-19 09:00AM  Lilly to Bring Half-Priced Version of Popular Humalog Insulin Zacks
Mar-04-19 11:34PM  What's in the Cards for Novavax (NVAX) This Earnings Season? Zacks
05:15PM  Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion Zacks
11:50AM  Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Benzinga
07:55AM  Report: Developing Opportunities within General Dynamics, Blackbaud, Sanofi, Magellan Midstream Partners, Air Transport Services Group, and Entergy Future Expectations, Projections Moving into 2019 GlobeNewswire
Mar-01-19 09:29AM  Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices Zacks
05:07AM  Philippines to charge officials of Sanofi, government over dengue deaths Reuters
Feb-28-19 10:19PM  [$$] Philippines to charge Sanofi employees over dengue drug Financial Times
02:44PM  Woburn's Abpro strengthens Chinese ties with immuno-oncology deal American City Business Journals
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia in adults and children; and Cablivi to treat acquired thrombotic thrombocytopenic purpura in adults. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, for hematologic malignancies; and Zaltrap, for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, a sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; consumer healthcare products for allergy, cough, cold, pain, nutrition, digestion, and others; and pediatric, influenza, adult and adolescent booster, meningitis, travel, and endemic vaccines. Sanofi was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerMar 08Sale412.17131,11554,041,31620,723,717Mar 12 08:19 PM
Sanofi10% OwnerSep 06Sale406.68104,55242,519,24923,654,384Sep 10 05:01 PM
Sanofi10% OwnerJun 08Sale309.31121,60137,611,88223,758,936Jun 11 04:30 PM